[HTML][HTML] Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients

JJ Veillette, SA Winans, VK Maskiewicz… - European Journal of …, 2021 - Springer
Abstract Background and Objective Standard piperacillin–tazobactam (PT) dosing may be
suboptimal in obesity, but high-dose regimens have not been studied. We prospectively …

[HTML][HTML] Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients

JJ Veillette, SA Winans, VK Maskiewicz… - European Journal of …, 2021 - ncbi.nlm.nih.gov
Methods Those receiving standard-dose PT with BMI≥ 30 kg/m 2 weighing 105–139 kg
or≥ 140 kg were given up to 6.75 g or 9 g every 6 h, respectively. Patients were monitored …

[引用][C] Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients

JJ Veillette, SA Winans… - … Journal of Drug …, 2021 - lomalinda.elsevierpure.com
Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese
Patients — Loma Linda University Skip to main navigation Skip to search Skip to main content …

Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin-Tazobactam in Obese Patients

JJ Veillette, SA Winans… - … journal of drug …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and objective Standard piperacillin-tazobactam (PT) dosing may be suboptimal
in obesity, but high-dose regimens have not been studied. We prospectively evaluated the …

Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin-Tazobactam in Obese Patients.

JJ Veillette, SA Winans, VK Maskiewicz… - European Journal of …, 2021 - europepmc.org
Methods Those receiving standard-dose PT with BMI≥ 30 kg/m 2 weighing 105-139 kg or≥
140 kg were given up to 6.75 g or 9 g every 6 h, respectively. Patients were monitored …